Thymic peptide fragment
TB-500
TB-500 is a seven-amino-acid fragment (LKKTETQ) of thymosin beta-4. FDA's May 2026 briefing identified no human pharmacokinetic study; the figures row shows the app's values, including a half-life of about 2 hours.1
TB-500 after one dose: 50% at ~2 h, 25% at 4 h, 12.5% at 6 h.
Drawn from the half-life in the app's model, ~2 h. The model's figures
- Compound
- TB-500
- Symbol
- TB5
- Family
- Healing peptides
- Parts
- 15
- References
- 20
- Checked
- Last reviewed . Sources are listed below.
Overview
TB-500 is described in FDA's briefing document for its July 2026 advisory committee meeting as a synthetic N-acetylated heptapeptide containing the amino acid sequence 17 through 23 (LKKTETQ) of the full-length, 43-amino-acid peptide thymosin beta-4.1 The document adds that TB-500 is a common name and not a United States Adopted Name, and that FDA has encountered multiple salts and derivatives sold under the same common name.1 A 2026 orthopaedic review states that TB-500 is "a distinct seven amino-acid fragment of TB-4 that is frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence."2
The app's entry describes TB-500 as a 43-amino acid peptide originally isolated from the thymus, which is the length of full-length thymosin beta-4, not of the seven-amino-acid fragment described above. FDA states that "thymosin beta-4 and TB-500 are not the same substance."1
FDA's briefing document, dated 15 May 2026, states that after a literature search "no articles were found in which TB-500 was administered to humans."1 A 2026 case report of three patients describes TB-500 10 mg weekly as one part of a multi-drug regimen, and a phase 1/2 trial of TB-500 is registered as recruiting with no results posted.3,4 A 2026 scoping review of six peptides, among them thymosin beta-4 or TB-500, reported that 67% of identified publications used preclinical animal models.5
How it works
Sources in this part
The actin-binding sequence
FDA's briefing document states that the segment LKKTET is known as the actin-binding region of thymosin beta-4, and that it has been hypothesized that LKKTETQ may share thymosin beta-4's capacity to buffer G-actin.1 A 2010 review by Sosne and colleagues in the FASEB Journal states that a short sequence containing LKKTETQ "promotes angiogenesis, wound healing, and cell migration."6 In cell and tissue work, Philp and colleagues at the National Institutes of Health (FASEB Journal, 2003) reported that thymosin beta-4 and its seven-amino-acid actin-binding motif showed near-identical activity at about 50 nM in endothelial cell migration and chick aortic arch sprouting assays.7
FDA lists two articles on the non-acetylated heptapeptide, Philp et al. 2003 and Shah et al. 2018, whose profile "cannot be directly extrapolated to the N-acetylated heptapeptide TB-500."1 FDA's Philp et al. 2003 is a different paper from the FASEB Journal study above: Wound Repair and Regeneration 11(1):19-24, on db/db diabetic and aged mice.1 As FDA describes it, a topical study of the non-acetylated heptapeptide in 26-month-old female mice found epidermal closure and collagen content at day 7 significantly increased, without a dose-response assessment.1
Cell results with TB-500 itself
In the 2024 study by Rahaman and colleagues at the Korea Institute of Science and Technology (Journal of Chromatography B), only the TB-500 metabolite Ac-LKKTE showed significant wound healing activity in fibroblasts compared with the control.8 FDA describes the experiment: scratch-wounded fibroblast cultures incubated for 8 hours with TB-500 (free base) at 50 µg/mL or vehicle showed wound closure that did not differ significantly, in a study that lacks a concentration-response analysis.1 The authors write that "the previously reported wound-healing activity of TB-500 in literature may be due to its metabolite Ac-LKKTE rather than the parent form."8
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2 h
- Bioavailability
- 95%
- Typical dose
- 2–5 mg/week
- Route
- SubQ
- Time to peak
- ~0.5 h
FDA states that it did not identify clinical studies in humans assessing the pharmacokinetics or pharmacodynamics of TB-500 by any route of administration.1 The measured data are from horses, rats and in vitro systems, and the table sets the app's figures beside them.
| Parameter | Value | Note |
|---|---|---|
| Half-life (the app's figure) | ~2 hours | None of the cited sources reports a half-life measured for TB-500; in horses, plasma was unquantifiable 6 to 10 hours after the dose |
| Time to peak (the app's figure) | ~0.5 hours | The app's figure; the horse study below reports a later peak |
| Time to peak, horses | 60 to 120 minutes | Plasma peaks of 0.05 and 0.08 ng/mL after 10 mg subcutaneous in thoroughbred geldings, number not stated (Ho and colleagues, 2012, as FDA describes it)1,9 |
| Bioavailability (the app's figure) | 95% | The app's figure; the horse study had no intravenous arm, which FDA states precluded absolute bioavailability1 |
| Metabolites in horses | C-terminal truncated, N-acetylated peptides | Plasma at about 2 hours held the parent peptide, its stereoisomer and metabolites M2 and M5; urine at about 6 hours also held M1, M2, M4 and M51 |
| Metabolites in rats | Ac-LK highest at 0 to 6 hours in rats; Ac-LKK detected up to 72 hours | Rahaman and colleagues (2024)8; FDA describes male Sprague-Dawley rats aged 6 weeks given 50 mg/kg intraperitoneally1 |
| Human in vitro systems | C-terminal truncated metabolites | FDA describes Rahaman and colleagues' 22-hour incubations with human kidney microsomes, human liver S9 and cytosol, human serum and rat liver microsomes (primary metabolites M2, M4, M5 and M6)1; Zvereva and colleagues (2016) reported M2 to M5 in 2-hour incubations and high metabolic activity1,10 |
| Route (the app's figure) | SubQ | The nomination FDA evaluated proposed intramuscular and subcutaneous routes1 |
The app's half-life, time to peak and bioavailability for TB-500 have no matching measurement in the sources cited here, so no concentration curve is drawn from them. The only dosing interval reported for TB-500 in people is the weekly injection in a 2026 case report of a multi-drug regimen.3
Full-length thymosin beta-4, a different substance, was given intravenously in a placebo-controlled study in healthy volunteers; Ruff and colleagues report that the single-dose profile showed a dose proportional response and "an increasing half-life with increasing dose," and the PubMed record gives no half-life values.11
Human studies
The first two rows concern TB-500; the last three concern full-length thymosin beta-4 or its recombinant form and are not TB-500 results.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| TB-500, Froum and colleagues, Frontiers in Oral Health 20263 | Case report of three patients with inferior alveolar nerve injury after dental procedures; described by the authors as hypothesis-generating and uncontrolled | 3 patients: a 38-year-old woman, an 85-year-old and a 48-year-old woman | TB-500 10 mg with ARA-290 4 mg, BPC-157 1 mg, dexamethasone 8 mg and bupivacaine, as weekly submucosal injections for 4 weeks | All three reported improved sensation: a residual region of almost 3 mm, a residual area of nearly 2 mm, and numbness diminished by nearly 95%; no treatment-associated adverse events documented; the authors state causality cannot be established |
| TB-500, registry entry NCT07487363, Hudson Biotech4 | Phase 1/2, randomized, placebo-controlled, sequential dose escalation in three cohorts at 3:1 TB-500 to placebo; recruiting | 80 adults aged 40 to 75 with stable atherosclerotic cardiovascular disease (estimated) | Dose levels not given in the entry; 8 weeks of dosing and 4 weeks of safety follow-up | No results posted; primary outcomes are treatment-emergent and serious adverse events |
| Thymosin beta-4, not TB-500, Ruff and colleagues, Annals of the New York Academy of Sciences 201011 | Randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta-4; the record states no funder, and the affiliation given is Healthcare Discoveries LLC d/b/a ICON Development Solutions | Four cohorts of 10 healthy volunteers | Single intravenous dose of 42, 140, 420 or 1260 mg (as the source states), then the same dose daily for 14 days | Adverse events infrequent and mild or moderate; no dose limiting toxicities or serious adverse events; after a single dose, a dose proportional response and a half-life that rose with dose |
| Thymosin beta-4, not TB-500, Sosne and Ousler, Clinical Ophthalmology 201512 | Single-center, double-masked, placebo-controlled phase II study in a controlled adverse environment model; study drug RGN-259 from RegeneRx, and the authors report no conflicts of interest | 72 subjects with moderate to severe dry eye, randomized 1:1 | 0.1% thymosin beta-4 ophthalmic solution or placebo for 28 days | Neither primary endpoint (ocular discomfort, inferior corneal staining) differed significantly; discomfort in the challenge on day 28 was 27% lower than placebo (P=0.0244); ocular treatment-emergent adverse events in 2 (5.6%) versus 5 (13.9%) on placebo; one subject withdrew for an adverse event (moderately severe vomiting, suspected unrelated) and the only two events suspected to be treatment-related were both on placebo; the summary line states no adverse events were observed |
| Recombinant human thymosin beta-4, not TB-500, Zhang and colleagues, Cardiovascular Research 202513 | Randomized, placebo-controlled, double-blind trial after percutaneous coronary intervention (PCI), reported with mouse experiments; one author is at the R&D center of Beijing Northland Biotech | 96 patients with ST-segment elevation myocardial infarction | Recombinant human thymosin beta-4, dose not given in the PubMed record; first dose within 8 hours after PCI in the group described; follow-up 90 days | In the group that received the first dose within 8 hours after PCI (n = 43), infarcted areas were significantly smaller than placebo at 90 days, with no placebo n given for that comparison; the overall difference between the thymosin beta-4 group and placebo (n = 96) was not significant |
Deeper analysis: the 2026 case report of three patients
Froum and colleagues (Frontiers in Oral Health, 2026) describe three patients with inferior alveolar nerve injury and numbness after dental surgery (implant placement, implant removal, and tooth extraction with grafting), who received weekly submucosal injections for 4 weeks that combined TB-500 10 mg, ARA-290 4 mg, BPC-157 1 mg, dexamethasone 8 mg and a local anaesthetic.3 The authors present the cases "solely as hypothesis-generating clinical observations" and state that all three patients received the same regimen, so "it is impossible to determine whether the observed clinical course resulted from one agent, a combination of agents, associations among interventions, or the expected natural history."3 The authors also list dexamethasone, local anaesthetic, placebo effects and regression to the mean as plausible alternative explanations, and note that follow-up duration was inconsistent, restricting evaluation of long-term stability.3 No treatment-associated adverse events were documented, and the authors declare no funding and no commercial or financial relationships.3
Animal and cell studies
Sources in this part
Deeper analysis: the 2026 rat Achilles tendon study
Biçer and colleagues, from an orthopaedics and traumatology clinic in Istanbul (Joint Diseases and Related Surgery, 2026), transected and repaired the Achilles tendon in 32 male Sprague-Dawley rats aged 12 weeks, 8 per group, with tendons harvested "for biomechanical testing or histological evaluation" and the per-test numbers not given.14 The groups were control, BPC-157 10 µg/kg/day, TB-500 60 µg/kg/day, and both together, all given intraperitoneally for four weeks.14 Maximum load to failure was higher in the BPC-157 and TB-500 groups than in controls, reaching significance in the TB-500 group (p < 0.05).14 Total Bonar scores were lower in the TB-500 group (p = 0.016) and total Movin scores were lower in the TB-500 and combined groups (p = 0.017 and p = 0.040), while the BPC-157 group's total scores were numerically lower without reaching significance.14 Collagen type I expression did not differ significantly among groups, whereas collagen type III expression differed significantly.14 The authors report that the combination "did not confer additional benefits compared to either agent alone," call the work an "exploratory rat model study," and write that the findings need "dose-optimization and longer-term studies."14 The PubMed record states no funder. This is a rat study and not a human result.14
Ho and colleagues at the Hong Kong Jockey Club Racing Laboratory (Journal of Chromatography A, 2012) developed a method to identify N-acetylated LKKTETQ and its metabolites in equine plasma and urine, and confirmed them in samples from horses given a single dose containing 10 mg of the peptide.9
Doses reported in studies
The doses below are as the sources report them; none is a label dose, because no TB-500 product is approved.1
| Source | Dose | Route | Frequency and length |
|---|---|---|---|
| The app's figure | 2 to 5 mg per week | Subcutaneous | Weekly; the app's typical dose range |
| Froum and colleagues 2026, 3 patients3 | TB-500 10 mg per session, with other agents | Submucosal injection | Weekly for 4 weeks |
| Ho and colleagues 2012, horses, as described by FDA1,9 | 10 mg | Subcutaneous | Single dose |
| Biçer and colleagues 2026, rats, four groups14 | 60 µg/kg/day | Intraperitoneal | Daily for 4 weeks |
| Thymosin beta-4, not TB-500, Ruff and colleagues 201011 | 42, 140, 420 or 1260 mg (as the source states) | Intravenous | Single dose, then daily for 14 days |
Sources in this part
Side effects reported
FDA's search of its adverse event reporting system through 26 March 2025 retrieved no reports for TB-500, and its literature search identified no cases of adverse events.1 A search of an FDA foods and supplements complaint system for 1 January 2004 to 10 March 2025 retrieved two cases about "blended TB-500 and BPC-157," and the reports did not include safety assessments.1 FDA states that reporting is voluntary and that it cannot make definitive conclusions regarding the safety of TB-500.1
FDA's BPC-157 briefing describes a 40-year-old woman who used a product containing BPC-157 and TB500 (5 mg/5 mg), labeled for research purposes only, subcutaneously twice daily and developed diffuse hyperpigmentation and gingival darkening after one week, with identical reactions on rechallenge after two weeks.15 FDA states the adverse events were "likely due to the drug product considering that the AEs occurred upon rechallenge," and that because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported events.15 That the reaction cannot be assigned to TB-500 either is an inference here, not FDA's wording.
In the 2026 case report, no treatment-associated adverse events were documented in three patients given TB-500 with other agents.3
FDA states that peptides given by injection may pose a significant risk for immunogenicity, "potentially amplified by aggregation as well as potential peptide-related impurities," and that it identified no clinical study of immunogenicity or aggregation for TB-500.1 The 2026 orthopaedic review states that commercial products marketed as TB-500 raise concerns about "identity, purity, concentration, sterility, and manufacturing consistency."2 On the full-length peptide, Sport Integrity Australia's page states there is "serious concern that it increases the spread and growth of cancer cells."16
Bloodwork and markers
Sources in this part
None of the human reports cited above reports a laboratory marker for TB-500. The registry entry for NCT07487363 lists brachial artery flow-mediated dilation, high-sensitivity C-reactive protein, NT-proBNP and exploratory vascular stiffness as secondary outcomes at 8 weeks, with no results posted in the record.4
Regulatory and anti-doping status
Deeper analysis: FDA's briefing document on TB-500
The briefing document, dated 15 May 2026 and prepared for the Pharmacy Compounding Advisory Committee meeting of 23 and 24 July 2026, was written by FDA staff including Bini Mathew and Suhail Kasim.1 It evaluates TB-500 (free base) and TB-500 acetate for wound healing, the use named in a nomination by Wells Pharmacy Network that was later withdrawn, and FDA states that it evaluated both on its own initiative because the nomination was inconsistent about which substance was meant.1
The document reports that FDA did not identify acute toxicity studies of TB-500, and states that "nonclinical pharmacological evidence is currently lacking to support the potential for TB-500 to promote wound healing, and nonclinical toxicological studies are not available to inform safety considerations."1 FDA proposes not adding TB-500 (free base) or TB-500 acetate to the 503A Bulks List, citing characterization, lack of historical use in compounding, lack of effectiveness evidence and unknown human safety.1
| Body | Statement |
|---|---|
| FDA, briefing document (15 May 2026)1 | Proposes not adding TB-500 (free base) or TB-500 acetate to the 503A Bulks List; states neither is a component of an FDA-approved drug |
| FDA, safety-risk page (content current 22 April 2026)17 | Lists "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" under "Bulk drug substances nominated but withdrawn"; states it "may pose risk for immunogenicity," that FDA has not identified any human exposure data, and that FDA "lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans." McDermott reports TB-500 was removed from Category 2 on 15 April 2026 because the nomination was withdrawn19 |
| FDA advisory committee, 23 July 202618,19 | Recommended adding TB-500, in free base and acetate forms, to the 503A Bulks List, against FDA staff's proposal not to add it; 8 yes, 6 no and 1 abstention. An advisory vote that does not itself add it to the list; McDermott reports FDA saying it rarely diverges from the committee's recommendations |
| WADA Prohibited List 202620 | Section S2.3 names "Thymosin-ß4 and its derivatives e.g. TB-500"; section S2 is prohibited at all times, in and out of competition |
| Sport Integrity Australia16 | States that thymosin beta-4 is not approved by the TGA and that a therapeutic use exemption would not be granted |
Healio reported differing reasons. One member voted yes "primarily because of the ongoing discrepancies in the information we're receiving"; one voted no "for the lack of fundamental information and data to evaluate and know how to use the drug, and with added concern that this particular drug is being used in combination with other peptides"; another voted no partly over "overlap between the function of thymosin beta-4 and its ability to promote tumor progression and metastasis." McDermott Will & Schulte states that rulemaking "could occur in 2027 or extend into a multi-year process" and that FDA "is expected to exercise some form of informal enforcement discretion in the interim."19 The tally comes from these two secondary reports; the sources cited here include no FDA record of the vote.
The WADA 2026 list came into effect on 1 January 2026.20 Sport Integrity Australia's page lists TB-500 among other names for thymosin beta-4, whereas FDA states they are different substances.16,1
Storage and handling
Sources in this part
No label exists for TB-500; these are the storage statements FDA reports. For TB-500 (free base), FDA cites a product data sheet: sealed, away from moisture and light, under nitrogen, at -80°C for 2 years or -20°C for a year as a powder, and in solvent at -80°C for 6 months or -20°C for one month. For TB-500 acetate, FDA cites a nominator's certificate of analysis recommending 2-8°C in a refrigerator or a freezer in a sealed container, and public-domain information of below -15°C, protected from light in a tightly closed container; the two acetate figures differ. FDA's conclusions are that the free base is stable below -20°C and the acetate below -15°C under reported storage conditions.1
What is not known
Sources in this part
FDA states that no clinical studies or human exposure data using TB-500 by any route were identified in its review, and that potential safety risks of TB-500 in humans are unknown.1 It also states that it remains unknown whether TB-500 (free base) and TB-500 acetate could have wound-healing properties in vivo.1 A query of PubMed on 15 November 2026 for "TB-500" in the title or summary text returned 31 records (an independent query, not a cited record), and a search of ClinicalTrials.gov for the term TB-500 returned one registered study, NCT07487363.4
The app's half-life of about 2 hours and 95% bioavailability have no measurement behind them in the sources cited here, and the horse study reports a plasma peak at 60 to 120 minutes against the app's 0.5 hours.1
Frequently asked questions
What is TB-500?
TB-500 is described by FDA as a synthetic N-acetylated heptapeptide containing amino acids 17 through 23 (LKKTETQ) of the 43-amino-acid peptide thymosin beta-4.1
Is TB-500 the same as thymosin beta-4?
What is the half-life of TB-500?
The app lists a half-life of about 2 hours for TB-500, and none of the sources cited here reports a measured half-life for it. In thoroughbred geldings (number not stated) given 10 mg subcutaneously, plasma TB-500 peaked at 0.05 and 0.08 ng/mL between 60 and 120 minutes and was unquantifiable 6 to 10 hours after the dose, as FDA describes the study.1 No human pharmacokinetic study was identified.1
How long does TB-500 take to peak?
The app lists a time to peak of about 0.5 hours for TB-500. In the horse study FDA describes, plasma TB-500 peaked between 60 and 120 minutes after a 10 mg subcutaneous dose; no human measurement is cited.1
Is TB-500 banned in sport?
Is TB-500 approved by the FDA?
What did the FDA advisory committee vote on TB-500?
The Pharmacy Compounding Advisory Committee recommended adding TB-500 (free base and acetate) to the 503A Bulks List on 23 July 2026, against FDA staff's proposal, voting 8 yes, 6 no and 1 abstention, as Healio and McDermott Will & Schulte report.18,19 The vote is advisory; McDermott reports FDA rarely diverges from committee recommendations.19
Has TB-500 been tested in humans?
FDA's briefing document, dated 15 May 2026, states that no articles were found in which TB-500 was administered to humans.1 A 2026 case report describes three patients given TB-500 10 mg weekly with other agents, and a phase 1/2 trial (NCT07487363) is registered as recruiting with no results posted.3,4
What side effects are reported with TB-500?
FDA's search of its adverse event reporting system through 26 March 2025 retrieved no reports for TB-500.1 One report for a product containing BPC-157 and TB500 describes hyperpigmentation and gingival darkening that recurred on rechallenge; FDA states the events were likely due to the product, but that a relationship to BPC-157 cannot be assessed because it held two peptides.15 The 2026 case report documented no treatment-associated adverse events in three patients.3
Do BPC-157 and TB-500 work better together?
Guides, tools and comparisons
References
- FDA. Briefing document for TB-500-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23-24 July 2026 (dated 15 May 2026). FDA briefing document
- Tham A, et al. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg 2026. PMID 42937313
- Froum S, et al. Case Report: Regenerative peptides for inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health 2026. PMID 42876687
- Hudson Biotech. TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD (TBRIDGE-CV). ClinicalTrials.gov NCT07487363. NCT07487363
- Tewari K, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med 2026. PMID 42578445
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010. PMID 20179146
- Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J 2003. PMID 14500546
- Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B 2024. PMID 38382158
- Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A 2012. PMID 23084823
- Zvereva I, et al. Comparison of various in vitro model systems of the metabolism of synthetic doping peptides. J Proteomics 2016. PMID 27569051
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010. PMID 20536472
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol 2015. PMC4445951
- Zhang Y, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res 2025. PMID 41229390
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg 2026. PMID 42542926
- FDA. Briefing document for BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23-24 July 2026. FDA briefing document (BPC-157)
- Sport Integrity Australia. Thymosin Beta-4 Peptide Hormone Information. Sport Integrity Australia
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. FDA safety-risk page
- Bascom E. FDA committee recommends looser restrictions for several peptides. Healio, 24 July 2026. Healio report
- McDermott Will & Schulte. PCAC backs majority of peptides in two-day public meeting. 27 July 2026. McDermott Will & Schulte summary
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In force 1 January 2026. WADA 2026 list